investors.foundationmedicine.comFoundation Medicine | A World-leading Molecular Insights Company

Skip to main content Log In Create an account Products & Services Back Explore About Our Products & Services Our Tests Back Our Tests Compare Our Tests FoundationOne CDx FoundationOne Liquid CDx FoundationOne Heme IHC Testing Provider Services Back Provider Services Overview Online Ordering & Report Integrations Clinical Research & Trial Matching Decision Support Biopharma Partner Services Back Biopharma Partner Services Overview Genomic Data Solutions Clinical Trial Solutions Companion Diagnostic Development & Commercialization Actionable Results Latest CDx Indication FoundationOne®Liquid CDx, the broadest FDA-approved liquid biopsy, is now the only blood-based comprehensive genomic profiling companion diagnostic (CDx) for Lynparza® (olaparib) in prostate cancer. Resource Center Back Explore View All Resources For Providers Back Provider FAQ What is Comprehensive Genomic Profiling? Which genes are tested? How do I order a Foundation Medicine test? View all Provider FAQs Provider Resources Why Comprehensive Genomic Profiling? Immunotherapy Biomarkers Billing and Financial Assistance View all Provider Resources For Biopharma Partners Back Biopharma Partner FAQ How can genomic data generated by Foundation Medicine tests be used for biomarker discovery? How can working with Foundation Medicine help facilitate drug development? How do I contact someone in the biopharma group to discuss a project? View all Biopharma Partner FAQs Biopharma Resources Biopharma Partner Services Biopharma Brochure View all Biopharma Resources For Patients Back Patient FAQs Do all test results lead to actionable treatment options? Does insurance cover my test? Do the tests apply to all types of cancer? View all Patient FAQs Patient Resources Patient Brochure Doctor Discussion Guide Financial Assistance Application View all Patient Resources Latest CDx Indication FoundationOne®Liquid CDx, the broadest FDA-approved liquid biopsy, is now the only blood-based comprehensive genomic profiling companion diagnostic (CDx) for Lynparza® (olaparib) in prostate cancer. News & Events Back Explore News & Events Press Releases Foundation Forward Blog Events Media Library Useful Information About Us Leadership Team Browse Publications About Us Back About Us Our Story Our History Leadership Team Contact Us Useful Information Testing Portfolio Why Comprehensive Genomic Profiling? Browse Publications Careers For Patients Order a Test Now FDA-approved: FoundationOne®Liquid CDx With the broadest gene panel of any FDA-approved blood-based test, FoundationOne Liquid CDx analyzes over 300 genes and has Medicare coverage for qualifying patients across all solid tumors.* Learn More Dismiss Directly Impacting Patient Care Today and Shaping the Future of Patient Care Tomorrow We are dedicated to a transformation in cancer care driven by the belief that the more we know about cancer’s molecular underpinnings, the better we can help physicians make the best treatment decisions for their patients. Through richer science, deeper insights, and stronger partnerships—we’re redefining the way cancer is treated. Advancing Cancer Care Together Every advancement we make today has the potential to help the next patient diagnosed tomorrow. In just ten years, we’ve made incredible progress—breakthroughs that have helped shift the treatment paradigm to directly impact patient care. Foundation Medicine, a leading decision insights company, is helping physicians connect their patients to the latest cancer treatment options—making precision medicine a reality for thousands. For Providers Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help guide treatment strategies for all of your advanced cancer patients. Provider Resources FoundationOne®CDx Liquid Biopsy: From an Improbable Idea, New Potential Emerges Provider FAQs For Biopharma Partners We provide actionable insights into the oncogenomics of both rare and common cancers, fueling discovery through commercialization by using a robust database and deep experience with FDA approvals. Biopharma Partner Resources An End-To-End Approach To Precision Medicine Biopharma Brochure Biopharma Partner FAQs For Patients Every cancer is unique. That’s why we are committed to providing specific genomic insights into your cancer to help your doctor guide a personalized care plan. Patient Resources Information For Patients Patient Brochure Patient FAQs More Than Numbers Our unique knowledge base, FoundationCore® , is one of the world's largest cancer genomic databases, with more than 400,000 genomic profiles. It is designed to evaluate the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and which treatments might work for which patients. This all helps researchers and biopharma companies develop new therapies, design better clinical trials, and advance precision medicine. >400k Patients Tested >50 Biopharma Partners >500 Peer-reviewed Publications Valuable Insights, Actionable Options Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services, financial assistance , and technology solutions to help support all aspects of patient care. Learn more about our products and services Patient Story Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test. We Continue to Drive for Future Breakthroughs in Patient Care Latest CDx Test FoundationOne®Liquid CDx is the broadest FDA-approved blood-based comprehensive genomic profiling test, providing guideline-recommended genomic results from a simple blood draw. Learn more about FoundationOne®Liquid CDx Additional Notes *Medicare and Medicare Advantage members have coverage of FoundationOne Liquid CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria. Important Safety Information Select FoundationOne CDx FoundationOne Liquid CDx FoundationOne CDx FoundationOne Liquid CDx FoundationOne CDx FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com . FoundationOne Liquid CDx FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a pati...